

Caroline Papeix

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9132024/publications.pdf>

Version: 2024-02-01

35
papers

2,646
citations

430874

18
h-index

361022

35
g-index

36
all docs

36
docs citations

36
times ranked

3287
citing authors

#	ARTICLE	IF	CITATIONS
1	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet</i> , The, 2018, 391, 1263-1273.	13.7	684
2	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. <i>Neurology</i> , 2018, 90, e1858-e1869.	1.1	401
3	Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 1079.	9.0	357
4	Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2007, 13, 256-259.	3.0	190
5	Aquaporin-4 antibody-negative neuromyelitis optica. <i>Neurology</i> , 2013, 80, 2194-2200.	1.1	157
6	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. <i>Annals of Neurology</i> , 2021, 89, 30-41.	5.3	123
7	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1377-1384.	3.0	89
8	Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. <i>Journal of Autoimmunity</i> , 2017, 79, 84-90.	6.5	67
9	Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. <i>Journal of Neurology</i> , 2019, 266, 1182-1193.	3.6	61
10	Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 24-31.	1.9	57
11	Efficacy of rituximab in refractory neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2016, 22, 955-959.	3.0	55
12	Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. <i>Revue Neurologique</i> , 2018, 174, 255-264.	1.5	47
13	Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 936-944.	3.0	37
14	Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. <i>Neurology</i> , 2019, 93, e635-e646.	1.1	36
15	Risk of relapse after natalizumab withdrawal. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e297.	6.0	34
16	Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102482.	2.0	28
17	Patterns of Objective and Subjective Burden of Informal Caregivers in Multiple Sclerosis. <i>Behavioural Neurology</i> , 2015, 2015, 1-10.	2.1	26
18	The long-term outcome of MOGAD: An observational national cohort study of 61 patients. <i>European Journal of Neurology</i> , 2021, 28, 1659-1664.	3.3	26

#	ARTICLE	IF	CITATIONS
19	Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder. <i>Neurology</i> , 2021, 96, e2006-e2015.	1.1	22
20	Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients. <i>European Journal of Neurology</i> , 2020, 27, 384-391.	3.3	19
21	Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders. <i>European Journal of Neurology</i> , 2021, 28, 3461-3466.	3.3	17
22	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1424-1456.	3.0	16
23	Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. <i>Revue Neurologique</i> , 2019, 175, 341-357.	1.5	15
24	MRI characteristics of MOG-Ab associated disease in adults: An update. <i>Revue Neurologique</i> , 2021, 177, 39-50.	1.5	15
25	Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2017, 82, 186-195.	5.3	14
26	Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. <i>Revue Neurologique</i> , 2021, 177, 980-994.	1.5	13
27	Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. <i>Revue Neurologique</i> , 2020, 176, 804-822.	1.5	9
28	COVID-19 infection in NMO/SD patients: a French survey. <i>Journal of Neurology</i> , 2021, 268, 1188-1190.	3.6	9
29	Untreated patients with multiple sclerosis: A study of French expert centers. <i>European Journal of Neurology</i> , 2021, 28, 2026-2036.	3.3	8
30	Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1794-1798.	3.0	7
31	Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study. <i>Neurology and Therapy</i> , 2022, 11, 633-658.	3.2	3
32	A dent in the head. <i>Lancet, The</i> , 2007, 370, 1854.	13.7	1
33	A comparative evaluation of different neuromyelitis optica spectrum disorder sets of criteria. <i>European Journal of Neurology</i> , 2020, 27, 2250-2256.	3.3	1
34	Multiple cervical dissections after Rituximab. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102105.	2.0	1
35	Altered Immune Phenotypes and HLA-DQB1 Gene Variation in Multiple Sclerosis Patients Failing Interferon β Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 628375.	4.8	0